Not just superior on the anti calcification front but in every aspect . Better EORs, better alignment due to AVRs catheter and a smaller dia valve ( due to less stitching ) make insertion of the TAVR easier and complications less likely . Less stitches + less calcification should prove to be a serious advantage when accessing the longevity of valves . As AVRs flow bench has shown the competitors valves fail years before AVRs . Time will tell but I am thinking our competitors are already seriously worried about AVRs advantages GLTATH
AGM recording - enjoy, page-31
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.71 |
Change
0.010(0.06%) |
Mkt cap ! $301.9M | |||
| Open | High | Low | Value | Volume |
| $16.00 | $16.01 | $15.49 | $3.254M | 230.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $15.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.20 | 700 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |